Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Join Barchart Premier for advanced OPTIONS screeners and volatility tools. FREE 30 Day Trial
Stocks | Futures | Watchlist | More
or
Cormedix Inc (CRMD)
Cormedix Inc (CRMD)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Profile for [[ item.sessionDateDisplayLong ]]

Company Info

Cormedix Inc 300 CONNELL DRIVE SUITE 4200 BERKELEY HEIGHTS NJ 07922 USA

www.cormedix.com P: 908-517-9500 F: 908-375-8272

Description:

CorMedix Inc. is a biopharmaceutical company focused on developing and commercializing therapeutic products for the prevention and treatment of infectious and inflammatory diseases. The Company is focused on developing its lead product Defencath (TM), a novel, antibacterial and antifungal solution designed to prevent costly and life-threatening bloodstream infections associated with the use of central venous catheters in patients undergoing chronic hemodialysis. Defencath has been designated by FDA as Fast Track and as a Qualified Infectious Disease Product, which provides an additional five years of marketing exclusivity, which will be added to the five years granted to a New Chemical Entity upon approval of the NDA. CorMedix also intends to develop Defencath as a catheter lock solution for use in oncology and total parenteral nutrition patients. It is leveraging its taurolidine technology to develop a pipeline of antimicrobial medical devices, with programs in surgical sutures and meshes, and topical hydrog

Key Statistics

Overview:

Market Capitalization, $K 194,034
Enterprise Value, $K 150,764
Shares Outstanding, K 54,812
Annual Sales, $ 70 K
Annual Net Income, $ -29,700 K
Last Quarter Sales, $ 0 K
Last Quarter Net Income, $ -9,740 K
EBIT, $ -41,680 K
EBITDA, $ -41,470 K
60-Month Beta 1.79
% of Insider Shareholders 3.60%
% of Institutional Shareholders 35.03%
Float, K 52,839
% Float 96.40%
Short Volume Ratio 0.32

Growth:

1-Year Return -14.77%
3-Year Return -51.97%
5-Year Return -60.22%
5-Year Revenue Growth -78.79%
5-Year Earnings Growth 75.33%
5-Year Dividend Growth 0.00%

Per-Share Information:

Most Recent Earnings -0.17 on 11/14/23
Latest Earnings Date 04/04/24
Earnings Per Share ttm -0.86
EPS Growth vs. Prev Qtr 32.00%
EPS Growth vs. Prev Year 0.00%
Annual Dividend Yield 0.00%
Dividend Payout Ratio 0.00%
Most Recent Split 1-5 on 03/26/19

CRMD Ratios

Ratio
Price/Earnings ttm 0.00
Price/Earnings forward N/A
Price/Earnings to Growth N/A
Return-on-Equity % -65.98%
Return-on-Assets % -59.01%
Profit Margin % -42,428.57%
Debt/Equity 0.00
Price/Sales 5,602.21
Price/Cash Flow N/A
Price/Book 2.33
Book Value/Share 1.52
Interest Coverage -1,008.67
Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar